| |
Anthracyclines or monoclonal antibodies based tyrosine kinase inhibitors (All patients [n=226]) |
Anthracyclines or monoclonal antibodies based tyrosine kinase inhibitors (patients with follow-up echo [n=81]) |
| |
No(n=177) |
Yes (n=49) |
P value |
No (n=46) |
Yes (n=35) |
P value |
| Demographics |
|
|
|
|
|
|
| Age, yrs |
49±15 |
50±13 |
0.83 |
49±17 |
50±11 |
0.71 |
| Female gender |
129(72.9%) |
48(98.0%) |
<0.0001 |
33(71.7%) |
34(97.1%) |
0.003 |
| Nationality |
|
|
0.80 |
|
|
0.70 |
| Lebanese |
130(73.4%) |
37(75.5%) |
|
38(82.6%) |
30(85.7%) |
|
| Iraqi |
41(23.2%) |
10(20.4%) |
|
8(17.4%) |
4(11.4%) |
|
| Others |
6(3.4%) |
2(4.1%) |
|
2(4.3%) |
1(2.9%) |
|
| Body mass index, kg/m2 |
27±5 |
28±5 |
0.21 |
27±5 |
28±6 |
0.83 |
| Body surface area, m2 |
1.8±0.2 |
1.8±0.1 |
0.65 |
1.8±0.2 |
1.8±0.1 |
0.70 |
| Comorbidities |
|
|
|
|
|
|
| Systolic blood pressure, mm Hg |
127±16 |
126±18 |
0.56 |
127±15 |
127±19 |
0.88 |
| Hypertension |
46(26.0%) |
11(22.4%) |
0.61 |
13(28.3%) |
7(20.0%) |
0.39 |
| Diabetes |
12(6.8%) |
8(16.3%) |
0.037 |
4(8.7%) |
6(17.1%) |
0.25 |
| Prior revascularization |
16(9.0%) |
1(2.0%) |
0.10 |
8(17.4%) |
1(2.9%) |
0.089 |
| Smoking history |
64(36.2%) |
17(34.7%) |
0.83 |
16(34.8%) |
16(45.7%) |
0.32 |
| Sedentary lifestyle |
150(84.7%) |
40(81.6%) |
0.48 |
40(87.0%) |
30(85.7%) |
0.87 |
| Breast cancer |
102(57.6%) |
45(91.8%) |
<0.001 |
28(60.9%) |
34(97.1%) |
<0.0001 |
| Creatinine, mg/dL |
0.76±0.4 |
0.68±0.2 |
0.20 |
0.72±0.2 |
0.65±0.1 |
0.10 |
| Glomerular filtration rate, ml/min/1.72m2 |
128±47 |
138±48 |
0.27 |
129±47 |
142±47 |
0.19 |
| Medications |
|
|
|
|
|
|
| Beta blockers |
38(21.5%) |
10(20.4%) |
0.87 |
12(26.1%) |
8(22.9%) |
0.74 |
| ACEi/ARB |
30(16.9%) |
10(20.4%) |
0.57 |
11(23.9%) |
6(17.1%) |
0.46 |
| Statins |
29(16.4%) |
6 (12.2%) |
0.48 |
9 (19.6%) |
5(14.3%) |
0.53 |
| Echocardiographic parameters |
|
|
|
|
|
|
| LVEDd/height, mm/m |
28±3 |
28±2 |
0.67 |
27±3 |
28±3 |
0.53 |
| LVESd/height, mm/m |
18±2 |
18±2 |
0.51 |
18±2 |
19±2 |
0.63 |
| LV mass index, g/m2 |
47±12 |
41±10 |
0.03 |
45±9 |
41±10 |
0.09 |
| Ejection fraction, % |
60±4 |
59±4 |
0.090 |
60±4 |
59±4 |
0.19 |
| Global longitudinal strain % |
-19.8±2 |
-19.7±2 |
0.91 |
-20.2±3 |
-19.8±2 |
0.68 |
| LA volume index, ml/m2 |
23±6 |
22±5 |
0.15 |
23±6 |
22±5 |
0.13 |
| E, cm/s |
75±18 |
72±18 |
0.30 |
76±18 |
70±16 |
0.14 |
| A, cm/s |
72±19 |
68±16 |
0.17 |
73±22 |
71±16 |
0.59 |
| E/A |
1.1±0.4 |
1.3±1.3 |
0.09 |
1.1±0.4 |
1.3±1.5 |
0.51 |
| Deceleration time, ms |
205±37 |
205±31 |
0.95 |
211±39 |
209±29 |
0.74 |
| e’ lateral, cm/s |
11±4 |
11±3 |
0.77 |
11±4 |
11±3 |
0.92 |
| E/e’ |
7.1±2.2 |
6.8±2.7 |
0.42 |
7.1±2.3 |
6.5±2 |
0.26 |
| TAPSE, mm |
23±13 |
21±3 |
0.29 |
22±3 |
21±4 |
0.14 |
| Right ventricular S’, cm/s |
14±3 |
12±2 |
0.001 |
14±2 |
12±2 |
0.008 |
| Systolic PAP, mm Hg |
28±5 |
28±7 |
1.0 |
29±6 |
28±6 |
0.73 |
| Baseline diastolic function |
|
|
0.42 |
|
|
0.35 |
| Normal |
102(57.6%) |
33(67.3%) |
|
24(52.2%) |
22(62.9%) |
|
| Grade I DD |
67(37.8%) |
15(30.6%) |
|
20(43.5%) |
13(37.1%) |
|
| Grade ≥2 DD |
8(4.5%) |
1(2.0%) |
|
2(4.3%) |
0(0%) |
|
| Worsening of diastolic function |
|
|
|
4(8.7%) |
10(28.6%) |
0.023 |
|
